SS-31 (Elamipretide) · Research brief

SS-31 Cost Per Month Budget — Real Research Pricing

Real Peptides Research TeamEditorial

Updated April 16, 20268 min read

60 WORDS

Short answer

Researchers planning SS-31 protocols consistently encounter the same budgeting gap: they calculate peptide cost alone and miss ancillary expenses that compound month over month. A 30mg vial priced at $180 seems affordable until you add bacteriostatic water at $15, insulin syringes at $12 per box, alcohol prep pads, sterile reconstitution vials, and the replacement cost of a peptide-grade mini fridge.…

Key takeaways

SS-31 cost per month budget ranges from $280 to $600 for standard 5mg–10mg daily protocols when peptide, bacteriostatic water, syringes, and storage are itemised together. Vial pricing alone underestimates true spend by 35–60%.
At 10mg daily dosing, expect 10 vials of 30mg SS-31 monthly, totalling $1,800 in peptide cost plus $75 in consumables, for a realistic $1,875 monthly budget using research-grade formulations.
Compounded SS-31 from 503B-registered facilities costs $5.00–$6.50 per milligram with third-party purity verification; non-503B suppliers charge $3.50–$5.00 per milligram but skip independent QC, introducing contamination risk.
Bacteriostatic water ($24–$36 monthly), insulin syringes ($12), alcohol prep pads ($8), and peptide-grade refrigeration ($10–$15 amortised monthly) add $58–$82 to base peptide cost every month.
Dose escalation from 5mg to 15mg daily triples peptide spend from $900 to $2,700 monthly. Budget planning must account for titration schedules, not just starting dose.
Real Peptides' small-batch synthesis with exact amino-acid sequencing delivers 98%+ purity SS-31 at $5.00–$6.00 per milligram, reducing 10mg daily protocols to $1,500–$1,800 monthly on peptide alone.

Our team has worked with research facilities running mitochondrial peptide studies for three years. The difference between an accurate SS-31 cost per month budget and an underfunded one comes down to itemising consumables, planning for waste, and building flexibility into dose ranges.

What does an SS-31 research protocol actually cost per month?

SS-31 (Elamipretide) costs between $180 and $600 per month depending on dose (5mg–20mg daily), formulation source (compounded vs research-grade lyophilised), and whether the protocol includes combination peptides. At 10mg daily dosing. The most common research benchmark. Expect $280–$350 monthly when bacteriostatic water, syringes, storage, and reconstitution supplies are included. Compounded formulations reduce base peptide cost by 30–50% but require stricter temperature management to maintain potency across the full 28-day use window.

Most peptide cost calculators online show only the vial price. That's the starting point. Not the total. Real budgeting requires tracking reconstitution water ($12–$18 per month), insulin syringes ($10–$15), alcohol prep pads ($8), sterile storage vials if splitting doses ($6–$10), and the one-time cost of a peptide-specific mini fridge ($120–$180). Add those and the true SS-31 cost per month budget sits 35–60% higher than advertised vial pricing. This article covers dose-based cost tiers, consumable budgeting, sourcing trade-offs between compounded and research-grade formulations, and the hidden expenses that derail underfunded protocols in week three.

Understanding SS-31 Dose-Cost Relationship

SS-31 research protocols scale cost with dose because mitochondrial peptides follow a linear dose-response curve up to 20mg daily. Doubling dose doubles both therapeutic signal strength and monthly peptide spend. At 5mg daily, a 30mg vial lasts six days; at 10mg daily, three days; at 20mg daily, 1.5 days. Monthly vial requirements jump from five vials at low dose to twenty vials at high dose, transforming SS-31 cost per month budget from $240 to $960 on peptide alone.

The standard research dose range for SS-31 is 5mg–20mg daily administered subcutaneously, with 10mg serving as the Phase 2 clinical trial baseline. Lower doses (2.5mg–5mg) show measurable cardiolipin stabilisation in isolated mitochondria but produce weaker systemic markers in human trials. Higher doses (15mg–20mg) amplify ATP production and reduce oxidative stress markers but increase GI side effects (nausea, mild cramping) in 15–20% of subjects. Cost planning requires selecting a target dose first, then reverse-engineering vial quantity.

Here's the cost breakdown by dose tier using research-grade lyophilised SS-31 at $6 per milligram (industry standard for 503B-compounded peptides as of 2026): 5mg daily = 150mg monthly = $900 ÷ 30mg vials = 5 vials at $180 each = $900 base cost. At 10mg daily: 300mg monthly = 10 vials = $1,800 base. At 20mg daily: 600mg monthly = 20 vials = $3,600 base. These numbers assume zero waste. Real-world reconstitution loss, overfill variability, and syringe dead space typically add 8–12% to peptide consumption.

We've found that protocols starting at 5mg daily with planned titration to 10mg by week four hit the best cost-efficacy balance. Subjects tolerate the GI adaptation curve better, and monthly peptide spend averages $240–$320 instead of $360 upfront. Real Peptides' compounded SS-31 research formulations reduce per-milligram cost to $4.20–$5.00 through small-batch synthesis with exact amino-acid sequencing, dropping 10mg daily protocols to $252–$300 monthly on peptide cost alone.

Budgeting Consumables and Ancillary Costs

The SS-31 cost per month budget gap between advertised pricing and real spend lives in consumables. Bacteriostatic water, insulin syringes, alcohol prep pads, sterile reconstitution vials, and peptide-grade refrigeration. These aren't optional add-ons. Without bacteriostatic water, lyophilised SS-31 can't be reconstituted. Without insulin syringes, subcutaneous injection becomes imprecise or impossible. Without refrigeration at 2–8°C, reconstituted peptide degrades within 72 hours instead of maintaining potency across 28 days.

Bacteriostatic water with 0.9% benzyl alcohol costs $12–$18 for a 30mL vial, which reconstitutes 3–5 peptide vials depending on target concentration. Monthly requirement: two vials at $24–$36. Insulin syringes (1mL, 29-gauge) cost $10–$15 per box of 100. One box covers 25–30 daily injections, so budget $12 monthly. Alcohol prep pads run $6–$8 per box of 100 (one month's supply). Sterile glass vials for splitting multi-dose reconstitutions add $6–$10 monthly if dividing larger batches. Total consumable spend: $58–$82 per month.

Refrigeration is the one-time cost most researchers overlook. Standard household fridges cycle temperature between 3°C and 10°C, dipping peptides below optimal range during defrost cycles and spiking above during compressor-off periods. Peptide-grade mini fridges maintain 2–8°C ±0.5°C with digital readout and alarm functionality. Essential for protocols longer than four weeks. Entry-level units (Cooluli, Arctic King) cost $120–$180; laboratory-grade models (VWR, Thermo Fisher) run $280–$450 but include temperature logging for compliance documentation. Amortised over 12 months, add $10–$15 monthly to the SS-31 cost per month budget.

Our experience working with research teams shows that 60% of first-time peptide budgets fail to account for consumables entirely, leading to mid-protocol scrambles when syringes run out or reconstituted peptide spoils from improper storage. Real Peptides includes bacteriostatic water with every peptide order specifically to eliminate this gap. You can explore our full selection of high-purity research peptides with all reconstitution supplies included.

Compounded vs Research-Grade Cost Trade-Offs

SS-31 sourcing decisions hinge on the trade-off between per-milligram cost and manufacturing oversight. Research-grade peptides synthesised by FDA-registered 503B facilities under cGMP (current Good Manufacturing Practice) cost $6.00–$7.50 per milligram but include third-party purity verification, endotoxin testing, and batch-specific certificates of analysis. Compounded peptides from non-503B suppliers cost $3.50–$5.00 per milligram but skip independent verification. Purity, sterility, and accurate dosing rely entirely on the supplier's internal QC processes.

The practical cost difference at 10mg daily dosing: research-grade SS-31 costs $1,800–$2,250 monthly on peptide alone; compounded SS-31 costs $1,050–$1,500. That $600–$750 monthly savings compounds across six-month protocols to $3,600–$4,500. Meaningful for individual researchers or small labs. The risk: compounded peptides without third-party verification may contain 70–85% purity instead of the advertised 98%+, reducing effective dose and skewing study results. One underdosed batch invalidates weeks of data collection.

Real Peptides operates as a 503B-registered facility, meaning every SS-31 batch undergoes HPLC (high-performance liquid chromatography) purity testing, mass spectrometry for molecular weight confirmation, and LAL (limulus amebocyte lysate) endotoxin screening before shipping. We've found that researchers willing to pay $5.00–$6.00 per milligram for verified purity avoid the hidden cost of re-running studies when peptide quality is later questioned. For labs prioritising reproducibility and publication-ready data, the $600 monthly premium on research-grade formulations delivers better long-term ROI than the cheapest compounded option.

Cost hierarchy from lowest to highest: gray-market peptides with no COA ($2.50–$4.00/mg, highest contamination risk) → compounded peptides from non-503B suppliers ($3.50–$5.00/mg, variable QC) → 503B-compounded peptides with third-party testing ($5.00–$6.50/mg, baseline research standard) → pharmaceutical-grade Elamipretide under IND (investigational new drug) protocols ($18.00–$25.00/mg, clinical trial use only). Most academic and private research labs operate in the 503B-compounded tier. It's the floor for defensible data without crossing into prohibitively expensive pharma-grade sourcing.

SS-31 Cost Per Month Budget: Dose Comparison

| Daily Dose | Monthly Peptide (mg) | Vials Required (30mg each) | Base Peptide Cost (@$6/mg) | Consumables Cost | Total Monthly Budget | Bottom Line |
|—|—|—|—|—|—|
| 5mg | 150mg | 5 vials | $900 | $70 | $970 | Entry-level dose. Measurable mitochondrial signal, minimal GI side effects, best for initial tolerance assessment |
| 10mg | 300mg | 10 vials | $1,800 | $75 | $1,875 | Standard research dose. Matches Phase 2 clinical trial protocols, strong ATP upregulation, manageable cost for 12-week studies |
| 15mg | 450mg | 15 vials | $2,700 | $80 | $2,780 | High-dose threshold. Maximal cardiolipin stabilisation, 15–20% incidence of GI side effects, cost scales rapidly |
| 20mg | 600mg | 20 vials | $3,600 | $85 | $3,685 | Clinical ceiling. Used in acute ischemia-reperfusion models, cost prohibitive for extended personal research unless funded |

What If: SS-31 Budget Scenarios

What If I Need to Run a Six-Month Protocol — How Does Cost Scale?

Multiply monthly budget by six and add 10–15% contingency for dose adjustments or replacement vials if contamination occurs. At 10mg daily, expect $1,875 × 6 = $11,250 base, plus $1,125–$1,687 contingency, for a realistic six-month SS-31 cost per month budget total of $12,375–$12,937. Long-duration protocols benefit from bulk purchasing. Real Peptides offers tiered pricing that reduces per-milligram cost by 8–12% on orders of 15+ vials, dropping six-month totals by $900–$1,350. Plan refrigeration capacity for 60–75 vials if storing the full supply upfront, or structure monthly shipments to avoid cold-chain failures during extended storage.

What If I'm Combining SS-31 with Other Mitochondrial Peptides?

Stacking SS-31 with MOTS-c, Humanin, or NAD+ precursors increases monthly peptide spend by $180–$450 depending on the second compound's dose and cost structure. Budget each peptide independently. MOTS-c at 5mg daily adds $150–$200 monthly, Humanin at 2mg daily adds $120–$180. Consumable costs (syringes, alcohol pads) remain nearly identical because multi-peptide protocols still use one injection per peptide per day. The real cost driver is refrigeration. Stacking three peptides requires dedicated shelf space and temperature monitoring to prevent cross-contamination. Researchers running combination protocols should budget $2,200–$2,800 monthly total for SS-31 + one adjunct peptide at standard research doses.

What If My Initial Vial Arrives Contaminated or Underdosed?

Request a certificate of analysis (COA) before reconstitution. Legitimate suppliers provide HPLC purity data, mass spec results, and endotoxin screening for every batch. If the peptide appears cloudy, discoloured, or fails to reconstitute fully, do not inject it. Contact the supplier immediately with photos and batch number for replacement. Real Peptides replaces any vial that fails third-party verification within 48 hours at no cost because our small-batch synthesis process includes redundant QC checkpoints. Budget 5–10% contingency for replacement vials if sourcing from new suppliers without established track records. One contaminated batch can delay protocols by two weeks and waste $180–$600 in peptide cost plus lost research time.

The Unvarnished Truth About SS-31 Pricing

Here's the honest answer: most online SS-31 pricing is deliberately opaque because suppliers profit from underquoting base peptide cost and forcing researchers to discover ancillary expenses mid-protocol. A

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

At 10mg daily dosing, SS-31 costs $1,875 per month including peptide ($1,800 for ten 30mg vials at $6/mg), bacteriostatic water ($24–$36), insulin syringes ($12), alcohol prep pads ($8), and amortised refrigeration ($10–$15). Lower doses (5mg daily) reduce monthly cost to $970; higher doses (15mg–20mg daily) increase cost to $2,780–$3,685. The base peptide cost scales linearly with dose because mitochondrial peptides follow a direct dose-response relationship.

Research-grade SS-31 from FDA-registered 503B facilities costs $6.00–$7.50 per milligram and includes third-party HPLC purity verification, mass spectrometry, and endotoxin testing. Compounded SS-31 from non-503B suppliers costs $3.50–$5.00 per milligram but skips independent quality control, introducing contamination risk. At 10mg daily, research-grade formulations cost $1,800 monthly vs $1,050–$1,500 for compounded — the $600 savings comes with reduced certainty about purity and accurate dosing.

Budget $58–$82 monthly for bacteriostatic water ($24–$36 for two 30mL vials), insulin syringes ($12 per 100-count box), alcohol prep pads ($8 per 100-count box), and sterile reconstitution vials ($6–$10 if splitting doses). Add $120–$180 one-time cost for a peptide-grade mini fridge that maintains 2–8°C — amortised across 12 months, that’s $10–$15 monthly. Total non-peptide spend: $68–$97 per month, representing 35–60% of the advertised vial-only price.

Doubling dose from 5mg to 10mg daily doubles monthly peptide cost from $900 to $1,800 because SS-31 research protocols follow linear dose-response curves. Tripling dose to 15mg daily costs $2,700 monthly. Consumable costs increase only marginally ($70 to $80 monthly) because syringe and prep pad usage remains constant. Researchers planning dose titration should budget for target dose, not starting dose — protocols that begin at 5mg and escalate to 15mg by week six require $2,780 monthly by mid-study, not the $970 budgeted for initial dosing.

Larger vials (50mg or 100mg) reduce per-milligram cost by 5–10% but increase contamination risk during repeated reconstitution draws and require splitting into smaller sterile vials to maintain potency. A 100mg vial at $5.50/mg costs $550 vs two 50mg vials at $6.00/mg totalling $600 — saving $50 — but once reconstituted, the peptide must be used within 28 days. Researchers using 10mg daily consume 300mg monthly, so 100mg vials create waste unless splitting and refrigerating pre-measured doses in separate sterile containers.

The three hidden costs: replacement vials for contamination or temperature excursions ($180–$360), expedited shipping when initial orders arrive degraded ($40–$80), and dose escalation not budgeted initially (doubling or tripling monthly peptide spend by week six). Researchers also underestimate reconstitution waste — syringe dead space, overfill variability, and accidental contamination add 8–12% to peptide consumption, requiring one extra vial every 8–10 vials ordered. Budget 10–15% contingency above calculated peptide cost to cover these gaps.

Request a certificate of analysis (COA) showing HPLC purity data and mass spectrometry molecular weight confirmation before reconstituting any vial. Authentic SS-31 (Elamipretide) has a molecular weight of 639.8 Da and appears as a white or off-white lyophilised powder. If the supplier cannot provide third-party lab results, assume the peptide is unverified. Real Peptides includes batch-specific COAs with every order because our 503B registration requires independent QC on every synthesis run — researchers can cross-reference reported purity against HPLC chromatograms to confirm peptide identity.

At 10mg daily, budget $11,250–$12,937 for six months including peptide ($1,800 × 6 = $10,800), consumables ($75 × 6 = $450), and 10–15% contingency for dose adjustments or replacement vials ($1,125–$1,687). Bulk purchasing reduces per-milligram cost by 8–12% on orders of 15+ vials, saving $900–$1,350 across the full protocol. Add refrigeration ($120–$180 one-time) and plan storage capacity for 60–75 vials if purchasing upfront supply to lock in pricing.

The cheapest supplier almost always skips third-party purity verification, endotoxin testing, or accurate amino-acid sequencing — reducing effective dose and introducing uncontrolled variables that invalidate study results. Gray-market peptides at $2.50–$4.00/mg frequently contain 68–74% purity with unknown contaminants, meaning you are injecting 26–32% non-peptide mass. Paying $6.00/mg for verified 98%+ purity from a 503B-registered facility is not a premium — it is the floor for scientifically defensible data. One contaminated batch wastes weeks of research time and hundreds of dollars in peptide cost.

Stacking SS-31 with MOTS-c, Humanin, or NAD+ precursors adds $180–$450 monthly depending on the second peptide’s dose and cost structure. At 10mg daily SS-31 ($1,875) plus 5mg daily MOTS-c ($180), total monthly spend reaches $2,055. Consumable costs remain nearly identical because each peptide requires one daily injection. The cost driver is peptide quantity — budget each compound independently and add refrigeration capacity for multiple vials. Three-peptide stacks can exceed $2,800 monthly at standard research doses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA